[1][2] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.
[1][2] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.
[1][2] The drug has reportedly been in pre-clinical development for all medical indications since 2008.
[3] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983.
This drug article relating to the nervous system is a stub.